Search: onr:"swepub:oai:DiVA.org:uu-459712" >
Infantile myofibrom...
Infantile myofibromatosis : Excellent prognosis but also rare fatal progressive disease. Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry
-
Sparber-Sauer, Monika (author)
-
Vokuhl, Christian (author)
-
Seitz, Guido (author)
-
show more...
-
Sorg, Benjamin (author)
-
Tobias, Möllers (author)
-
von Kalle, Thekla (author)
-
Münter, Marc (author)
-
Bielack, Stefan S (author)
-
Ladenstein, Ruth (author)
-
- Ljungman, Gustaf, 1958- (author)
- Uppsala universitet,Institutionen för kvinnors och barns hälsa
-
Niggli, Felix (author)
-
Frühwald, Michael (author)
-
Loff, Stefan (author)
-
Klingebiel, Thomas (author)
-
Koscielniak, Ewa (author)
-
show less...
-
(creator_code:org_t)
- 2021-10-11
- 2022
- English.
-
In: Pediatric Blood & Cancer. - : John Wiley & Sons. - 1545-5009 .- 1545-5017. ; 69:3
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: Infantile myofibromatosis (IM) is a rare benign soft tissue tumor and often a self-limiting disease but rarely includes life-threatening complications. Little is known about optimal treatment of primary localized (LD) and multifocal disease (MFD).Methods: Treatment and outcome of 95 children with IM registered within five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry (1981-2016) were evaluated.Results: LD was diagnosed in 71 patients at a median age of 0.4 years (range 0.0-17.7). MFD was present in 24 patients. The mainstay of treatment was watch-and-wait strategy (w&w) after initial biopsy or resection. Low-dose chemotherapy (CHT) was administered to 16/71 (23%) patients with LD and eight of 24 (33%) patients with MFD, imatinib was added in two. A delayed resection was possible in eight of 71 (11%) and five of 24 (21%) patients with LD and MFD, respectively. Overall, patients were alive in complete remission (n = 77) and partial remission (n = 10) at a median follow-up time of 3.4 years after diagnosis (range 0.01-19.4); no data available (n = 5). Three patients died of progressive disease (PD) despite CHT. Gender, tumor size, and location correlated with a favorable event-free survival (EFS) in patients with LD. The 5-year EFS and overall survival of patients with LD were 73% (±12, confidence interval [CI] 95%) and 95% (±6, CI 95%), respectively; for MFD 51% (±22, CI 95%) and 95% (±10, CI 95%).Cconclusion: Prognosis is excellent in patients with LD and MFD. Targeted treatment needs to be evaluated for rare fatal PD.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- CWS Group
- infantile myofibromatosis
- infants and children
- localized and multifocal disease
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Sparber-Sauer, M ...
-
Vokuhl, Christia ...
-
Seitz, Guido
-
Sorg, Benjamin
-
Tobias, Möllers
-
von Kalle, Thekl ...
-
show more...
-
Münter, Marc
-
Bielack, Stefan ...
-
Ladenstein, Ruth
-
Ljungman, Gustaf ...
-
Niggli, Felix
-
Frühwald, Michae ...
-
Loff, Stefan
-
Klingebiel, Thom ...
-
Koscielniak, Ewa
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Pediatric Blood ...
- By the university
-
Uppsala University